A Phase 2 interventional study of Aerobic exercise and Duloxetine in Knee Osteoarthritis and Depression, sponsored by University of Maryland, Baltimore. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing duloxetine in Osteoarthritis, Knee — 4 open to participants now, 4 under way, none of them phase 3. duloxetine · Osteoarthritis, Knee.
Among the 19 studies testing duloxetine in Osteoarthritis, Knee, this one is the 16th largest by enrollment, is one of 3 that started in 2021, is one of 3 in phase 2, and was the 10th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →4 of the 19 studies testing duloxetine in Osteoarthritis, Knee are open now, in 2 countries. Recruiting first, the newest first:
Benedict Alter · Sites in United States
Ages 45–80
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 50+
Northwestern University · Sites in United States
Ages 41+
VA Office of Research and Development · Sites in United States
Ages 40+ · Healthy volunteers
By country, each count listing its studies:
duloxetine: first FDA approval 2004 (CYMBALTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 7 · Phase 4 6
First in 2006; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 102 across the 19 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 19 have an industry lead sponsor. The 10 most frequent:
University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.
Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.
University of Maryland, Baltimore has 5 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
1 of the studies testing duloxetine in Osteoarthritis, Knee that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423716Sunnybrook Health Sciences CentreEffect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE) | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing duloxetine in Osteoarthritis, Knee, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the addition of duloxetine to aerobic exercise in the treatment of symptomatic knee osteoarthritis and depressive symptoms in adults. All participants will receive the receive the treatment protocol, which will first be evaluated in terms of feasibility and then pilot tested.
Symptomatic knee osteoarthritis (OA) affects 10% of men and 13% of women 60 years or older, and depressive symptoms are common, occurring in one-fifth of these patients. Depressive symptoms worsen knee OA disease severity and are a barrier to pain management and engagement in physical activity. Guidelines recommend depression treatment in older adults with knee OA but provide no direction on how to simultaneously manage the co-occurrence of physical and mental morbidity. Treatment recommendations advise exercise to manage pain and disability and improve psychosocial health in knee OA patients; however, compliance to exercise programs is low in persons with chronic pain and disability and is only made worse by comorbid depression. Adherence is critical to the efficacy of depression treatments using exercise training, and no such exercise program has ever been designed for and tested in OA patients with co-occurring depressive symptoms in a way to enhance compliance. Duloxetine is the only antidepressant medication indicated for pain management in knee OA patients that has demonstrated efficacy and tolerability when treating depression in older adults and is a viable pharmacological complement to exercise. There are no protocols that combine treatments using interventions that affect symptoms of both knee OA and depression, and the study goals are to evaluate the feasibility of and then pilot test a protocol comprised of aerobic exercise training plus duloxetine for the treatment of symptomatic knee OA and comorbid depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will have a starting duloxetine dosage of 30 mg/day and be titrated up to a daily optimal dosage of 60 mg/day as tolerated during the first 12-weeks of the study. Twelve weeks after the receipt of their prescription, participants will be evaluated for the need to increase medication dosage to 90 mg/day. After duloxetine initiation, participants will be provided an exercise prescription that includes a progressive walking program aiming to achieve 50 minutes of moderate-intensity physical activity, three times per week, over 24 weeks.
Behavioral: Aerobic exercise · Drug: Duloxetine
Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
Knee Osteoarthritis Outcomes Scale (KOOS) Pain Subscale
The self-reported KOOS pain subscale is sensitive to changes in knee OA symptoms, and consists of nine items scored on a Likert scale (0 \[No problems\] to 4 \[Extreme Problems\]) that ranges from 0-36, with higher values indicating greater severity.
Time frame: Change from Baseline Pain Severity at 12 weeks
Hamilton Depression Rating Scale (HAM-D)
The HAM-D is clinician-administered, 21-item questionnaire, designed to rate the severity of depression in patients. Individual scores are based on the first 17 items, each with a possible score of 0-4 (0=Absent; 4=Extreme Symptoms) or 0-2 (0=Absent; 2=Frequent), yielding an overall range of 0-54. Higher scores indicate greater depression severity.
Time frame: Change from Baseline Depression Severity at 12 weeks
Participants with symptomatic knee osteoarthritis and depressive symptoms were recruited from the University of Maryland Medical System, the Veterans Affairs Maryland Health Care System, and the surrounding Baltimore metropolitan area. Participants were enrolled sequentially into the center-based Duloxetine and Exercise for Knee Osteoarthritis and Depression (DEKODE) feasibility cohort and the subsequent hybrid Duloxetine and Exercise for Knee Osteoarthritis (DEKO) pilot cohort.
| Milestone | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine |
|---|---|---|
| Started | 9 | 34 |
| Completed | 1 | 17 |
| Not completed | 8 | 17 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 7 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Did not meet eligibility criteria | 6 | 7 |
| Withdrew: Adverse event | 1 | 0 |
The self-reported KOOS pain subscale is sensitive to changes in knee OA symptoms, and consists of nine items scored on a Likert scale (0 \[No problems\] to 4 \[Extreme Problems\]) that ranges from 0-36, with higher values indicating greater severity.
| score | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine |
|---|---|---|
| Knee Osteoarthritis Outcomes Scale (KOOS) Pain Subscale | 2.8 | 14.2 ± 15.0 |
The HAM-D is clinician-administered, 21-item questionnaire, designed to rate the severity of depression in patients. Individual scores are based on the first 17 items, each with a possible score of 0-4 (0=Absent; 4=Extreme Symptoms) or 0-2 (0=Absent; 2=Frequent), yielding an overall range of 0-54. Higher scores indicate greater depression severity.
| score | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine |
|---|---|---|
| Hamilton Depression Rating Scale (HAM-D) | -24 | -5.5 ± 6.8 |
Collected over Up to 24 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Center-Based Aerobic Exercise Plus Duloxetine | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Hybrid Aerobic Exercise Plus Duloxetine | 0/34 (0%) | 0/34 (0%) | 10/34 (29.4%) |
| Event | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/9 | 0/34 |
| Arrhythmia during graded exercise testCardiac disorders | 1/9 | 0/34 |
| NauseaGastrointestinal disorders | 0/9 | 3/34 |
| FallInjury, poisoning and procedural complications | 0/9 | 2/34 |
| Stomach painGastrointestinal disorders | 0/9 | 2/34 |
| Positive COVID testInfections and infestations | 0/9 | 1/34 |
| Sexual dysfunctionReproductive system and breast disorders | 0/9 | 1/34 |
| DrowsinessNervous system disorders | 0/9 | 1/34 |
| Gastrointestinal symptomsGastrointestinal disorders | 0/9 | 1/34 |
| Age, Continuous(years) | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine | Total |
|---|---|---|---|
| Mean | 64.7 ± 7.40 | 61.4 ± 10.2 | 62.1 ± 9.7 |
| Sex: Female, Male(Participants) | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine | Total |
|---|---|---|---|
| Female | 7 | 22 | 29 |
| Male | 2 | 12 | 14 |
| Race (NIH/OMB)(Participants) | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 16 | 24 |
| White | 1 | 16 | 17 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 9 | 32 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain(score) | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine | Total |
|---|---|---|---|
| Mean | 41.7 ± 0 | 49.34 ± 14.54 | 48.7 ± 14.0 |
| 6-Minute Walk Distance(feet) | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine | Total |
|---|---|---|---|
| Mean | — | 1222.6 ± 250.8 | 1222.6 ± 250.8 |
| 30-Second Chair Stand Test(stands) | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine | Total |
|---|---|---|---|
| Mean | — | 9.1 ± 3.2 | 9.1 ± 3.2 |
| Timed Up and Go Test(seconds) | Center-Based Aerobic Exercise Plus Duloxetine | Hybrid Aerobic Exercise Plus Duloxetine | Total |
|---|---|---|---|
| Mean | — | 12.0 ± 3.2 | 12.0 ± 3.2 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Aug 2025, 46 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 43 non-industry phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's 46 months is above that.
Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duloxetine
University of Maryland, Baltimore →